Corcept therapeutics director sells $117,920 in stock

Published 12/03/2025, 21:58
Corcept therapeutics director sells $117,920 in stock

Daniel N. Swisher Jr., a director at Corcept Therapeutics Inc. (NASDAQ:CORT), has recently sold 2,200 shares of common stock, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $53.60 each, totaling $117,920. This transaction was conducted under a pre-established 10b5-1 plan. The sale comes as CORT shares have delivered impressive returns, surging over 126% in the past year and 55% in the last six months. According to InvestingPro, the company maintains a GREAT financial health score, with a market capitalization of $5.8 billion.

In conjunction with the sale, Swisher exercised stock options to acquire 2,200 shares at a price of $12.13 per share. Following these transactions, Swisher holds no shares directly. The stock option exercise was fully exercisable, with an expiration date set for May 24, 2027. Trading at a P/E ratio of 40.7x, InvestingPro analysis reveals 14 additional key insights about CORT’s valuation and growth prospects, available in the comprehensive Pro Research Report.

In other recent news, Corcept Therapeutics reported its fourth-quarter earnings for 2024, revealing a shortfall in both earnings per share (EPS) and revenue compared to analyst forecasts. The company’s EPS was $0.26, missing the projected $0.38, while revenue stood at $181.89 million, below the expected $198.05 million. Despite these misses, Corcept demonstrated robust annual growth with a 40% increase in revenue, totaling $675 million for the year, and a 33% rise in net income to $141 million. Additionally, Corcept’s new drug application for relacorilant, intended for treating Cushing’s syndrome, has been accepted by the FDA, with a decision expected by December 30, 2025. The company is optimistic about relacorilant, supported by positive results from various clinical trials, including the GRACE and GRADIENT studies. Furthermore, Corcept is expanding its market for hypercortisolism treatments and exploring relacorilant’s potential in oncology. Analysts from firms like Piper Sandler and H.C. Wainwright are closely monitoring Corcept’s developments, particularly the progress of the ROSELLA study in ovarian cancer. These recent developments indicate Corcept’s ongoing efforts to expand its therapeutic offerings and address operational challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.